Knockdown of PLAT enhances the anticancer effect of gefitinib in non-small cell lung cancer.

ABSTRACT:

Background

Tyrosine kinase inhibitors (TKIs), such as gefitinib, are widely used as standard treatments for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. However, the subsequent inevitable drug resistance has become a major challenge in clinical treatment. The aim of this study was to investigate the role of tissue-type plasminogen activator (PLAT) in gefitinib resistance in NSCLC.

Methods

The function of PLAT was determined using gefitinib-resistant cells and a nude mouse model. The gene knockdown was achieved by Lentivirus based RNA silence technique. Expression of relevant genes and proteins, cell viability, proliferation, apoptosis, cell cycle, reactive oxygen species levels, mitochondrial membrane poten

SUBMITTER: Yan M 

PROVIDER: S-EPMC7139041 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature